FA
PACB icon

FDx Advisors’s Pacific Biosciences PACB Stock Holding History

FDx Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-19,181
Closed -$188K – 557
2023
Q4 		$188K Buy
19,181
+815
+4% +$6.67K 0.01% 656
2023
Q3 		$153K Buy
18,366
+4,378
+31% +$50K 0.01% 607
2023
Q2 		$186K Buy
13,988
+1,733
+14% +$21.1K 0.01% 721
2023
Q1 		$100K Hold
12,255
– – ﹤0.01% 731
2022
Q4 		$100K Buy
12,255
+1,177
+11% +$10.1K ﹤0.01% 731
2022
Q3 		$64K Sell
11,078
-753
-6% -$4.32K ﹤0.01% 723
2022
Q2 		$52K Sell
11,831
-980
-8% -$5.96K ﹤0.01% 800
2022
Q1 		$117K Buy
+12,811
New +$147K ﹤0.01% 808

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

FDx Advisors's PACB Position: Q1 2024 in Review

FDx Advisors sold out of Pacific Biosciences (PACB) in Q1 2024, closing a stake of 19,181 shares — an estimated $188K sold.

FDx Advisors first reported a position in PACB in Q1 2022 and held it in 8 quarters. The position peaked at $188K in Q4 2023. 268 funds tracked by Wall St. Rank hold PACB as of Q1 2024.

  • FDx Advisors reported no remaining Pacific Biosciences position as of Q1 2024 after selling out during the quarter.
  • FDx Advisors sold 19,181 Pacific Biosciences shares in Q1 2024, an estimated $188K.
  • FDx Advisors first reported a position in Pacific Biosciences in Q1 2022 and held it in 8 quarters.
  • FDx Advisors's Pacific Biosciences position peaked at $188K in Q4 2023.
  • 268 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2024.

Based on FDx Advisors's 13F filing for Q1 2024, filed 3 May 2024.